FORA Capital LLC Purchases New Shares in ADMA Biologics, Inc. (NASDAQ:ADMA)

FORA Capital LLC purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 41,547 shares of the biotechnology company’s stock, valued at approximately $831,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. D. E. Shaw & Co. Inc. raised its holdings in ADMA Biologics by 26.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after buying an additional 1,442,799 shares during the period. Assenagon Asset Management S.A. raised its holdings in ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after buying an additional 92,281 shares during the period. Driehaus Capital Management LLC raised its holdings in ADMA Biologics by 17.3% in the 2nd quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock valued at $33,860,000 after buying an additional 447,743 shares during the period. Renaissance Technologies LLC raised its holdings in ADMA Biologics by 28.7% in the 2nd quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock valued at $28,868,000 after buying an additional 575,100 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in ADMA Biologics by 11.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,401,533 shares of the biotechnology company’s stock valued at $48,007,000 after buying an additional 249,412 shares during the period. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Performance

Shares of ADMA opened at $21.83 on Friday. The stock has a 50 day moving average price of $19.08 and a 200 day moving average price of $15.23. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $5.16 billion, a price-to-earnings ratio of 77.96 and a beta of 0.64. ADMA Biologics, Inc. has a 52-week low of $3.60 and a 52-week high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period in the prior year, the company posted $0.01 earnings per share. Research analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Analyst Ratings Changes

ADMA has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. Raymond James boosted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th. Finally, HC Wainwright boosted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th.

Insider Activity

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.